THTX

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.880

Open

2.860

VWAP

2.84

Vol

201.83K

Mkt Cap

63.91M

Low

2.785

Amount

572.59K

EV/EBITDA(TTM)

11.75

Total Shares

45.98M

176.78M

EV/OCF(TTM)

P/S(TTM)

1.59

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

17.51M

-20.61%

21.69M

-3.6%

23.63M

-5.25%

Estimates Revision

The market is revising Downward the revenue expectations for Theratechnologies Inc. (THTX) for FY2025, with the revenue forecasts being adjusted by -2.95% over the past three months. During the same period, the stock price has changed by 97.22%.

Revenue Estimates for FY2025

Revise Downward

-2.95%

In Past 3 Month

Stock Price

Go Up

+97.22%

In Past 3 Month

2 Analyst Rating

5.63% Upside

Wall Street analysts forecast THTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for THTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

5.63% Upside

Current: 2.840

Low

3.00

Averages

3.00

High

3.00

5.63% Upside

Current: 2.840

Low

3.00

Averages

3.00

High

3.00

Jones Trading

Justin Walsh

Strong Buy

Hold

Downgrades

n/a

2024-10-11

Reason

Jones Trading

Justin Walsh

Price Target

n/a

2024-10-11

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Theratechnologies Inc (THTX.O) is 17.88, compared to its 5-year average forward P/E of 4.47. For a more detailed relative valuation and DCF analysis to assess Theratechnologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.47

Current PE

17.88

Overvalued PE

42.39

Undervalued PE

-33.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

121.98

Current EV/EBITDA

11.29

Overvalued EV/EBITDA

539.82

Undervalued EV/EBITDA

-295.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.91

Current PS

1.50

Overvalued PS

3.10

Undervalued PS

0.72